efimosfermin

News

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

Digital

Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.

Sales & Marketing

The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.